Literature DB >> 25247519

Accuracy of FDG-PET to diagnose lung cancer in areas with infectious lung disease: a meta-analysis.

Stephen A Deppen1, Jeffrey D Blume2, Clark D Kensinger3, Ashley M Morgan4, Melinda C Aldrich5, Pierre P Massion6, Ronald C Walker7, Melissa L McPheeters8, Joe B Putnam9, Eric L Grogan1.   

Abstract

IMPORTANCE: Positron emission tomography (PET) combined with fludeoxyglucose F 18 (FDG) is recommended for the noninvasive diagnosis of pulmonary nodules suspicious for lung cancer. In populations with endemic infectious lung disease, FDG-PET may not accurately identify malignant lesions.
OBJECTIVES: To estimate the diagnostic accuracy of FDG-PET for pulmonary nodules suspicious for lung cancer in regions where infectious lung disease is endemic and compare the test accuracy in regions where infectious lung disease is rare. DATA SOURCES AND STUDY SELECTION: Databases of MEDLINE, EMBASE, and the Web of Science were searched from October 1, 2000, through April 28, 2014. Articles reporting information sufficient to calculate sensitivity and specificity of FDG-PET to diagnose lung cancer were included. Only studies that enrolled more than 10 participants with benign and malignant lesions were included. Database searches yielded 1923 articles, of which 257 were assessed for eligibility. Seventy studies were included in the analysis. Studies reported on a total of 8511 nodules; 5105 (60%) were malignant. DATA EXTRACTION AND SYNTHESIS: Abstracts meeting eligibility criteria were collected by a research librarian and reviewed by 2 independent reviewers. Hierarchical summary receiver operating characteristic curves were constructed. A random-effects logistic regression model was used to summarize and assess the effect of endemic infectious lung disease on test performance. MAIN OUTCOME AND MEASURES: The sensitivity and specificity for FDG-PET test performance.
RESULTS: Heterogeneity for sensitivity (I2 = 87%) and specificity (I2 = 82%) was observed across studies. The pooled (unadjusted) sensitivity was 89% (95% CI, 86%-91%) and specificity was 75% (95% CI, 71%-79%). There was a 16% lower average adjusted specificity in regions with endemic infectious lung disease (61% [95% CI, 49%-72%]) compared with nonendemic regions (77% [95% CI, 73%-80%]). Lower specificity was observed when the analysis was limited to rigorously conducted and well-controlled studies. In general, sensitivity did not change appreciably by endemic infection status, even after adjusting for relevant factors. CONCLUSIONS AND RELEVANCE: The accuracy of FDG-PET for diagnosing lung nodules was extremely heterogeneous. Use of FDG-PET combined with computed tomography was less specific in diagnosing malignancy in populations with endemic infectious lung disease compared with nonendemic regions. These data do not support the use of FDG-PET to diagnose lung cancer in endemic regions unless an institution achieves test performance accuracy similar to that found in nonendemic regions.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25247519      PMCID: PMC4315183          DOI: 10.1001/jama.2014.11488

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  98 in total

Review 1.  Histoplasmosis and blastomycosis.

Authors:  R W Bradsher
Journal:  Clin Infect Dis       Date:  1996-05       Impact factor: 9.079

Review 2.  Neuroendocrine-related biochemistry in the spectrum of human lung cancers.

Authors:  S B Baylin; R D Jackson; G Goodwin; A F Gazdar
Journal:  Exp Lung Res       Date:  1982-11       Impact factor: 2.459

3.  Visual and semiquantitative analyses for F-18 fluorodeoxyglucose PET scanning in pulmonary nodules 1 cm to 3 cm in size.

Authors:  Hiroaki Nomori; Kenichi Watanabe; Takashi Ohtsuka; Tsuguo Naruke; Keiichi Suemasu; Kimiichi Uno
Journal:  Ann Thorac Surg       Date:  2005-03       Impact factor: 4.330

Review 4.  Acquisition protocol considerations for combined PET/CT imaging.

Authors:  Thomas Beyer; Gerald Antoch; Stefan Müller; Thomas Egelhof; Lutz S Freudenberg; Jörg Debatin; Andreas Bockisch
Journal:  J Nucl Med       Date:  2004-01       Impact factor: 10.057

5.  [18F]FLT PET for diagnosis and staging of thoracic tumours.

Authors:  Helmut Dittmann; Bernhard Matthias Dohmen; Frank Paulsen; Kai Eichhorn; Susanne Martina Eschmann; Marius Horger; Manfred Wehrmann; Hans Juergen Machulla; Roland Bares
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-07-26       Impact factor: 9.236

6.  The utility of 99mTc depreotide compared with F-18 fluorodeoxyglucose positron emission tomography and surgical staging in patients with suspected non-small cell lung cancer.

Authors:  Daniel Kahn; Yusuf Menda; Kemp Kernstine; David Bushnell; Kelley McLaughlin; Sara Miller; Kevin Berbaum
Journal:  Chest       Date:  2004-02       Impact factor: 9.410

7.  Early lung-cancer detection with spiral CT and positron emission tomography in heavy smokers: 2-year results.

Authors:  Ugo Pastorino; Massimo Bellomi; Claudio Landoni; Elvio De Fiori; Patrizia Arnaldi; Maria Picchio; Giuseppe Pelosi; Peter Boyle; Ferruccio Fazio
Journal:  Lancet       Date:  2003-08-23       Impact factor: 79.321

8.  The performance of( 18)F-fluorodeoxyglucose positron emission tomography in small solitary pulmonary nodules.

Authors:  Gerarda J Herder; Richard P Golding; Otto S Hoekstra; Emile F Comans; Gerrit J Teule; Pieter E Postmus; Egbert F Smit
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-06-03       Impact factor: 9.236

Review 9.  Test performance of positron emission tomography and computed tomography for mediastinal staging in patients with non-small-cell lung cancer: a meta-analysis.

Authors:  Michael K Gould; Ware G Kuschner; Chara E Rydzak; Courtney C Maclean; Anita N Demas; Hidenobu Shigemitsu; Jo Kay Chan; Douglas K Owens
Journal:  Ann Intern Med       Date:  2003-12-02       Impact factor: 25.391

10.  The development of QUADAS: a tool for the quality assessment of studies of diagnostic accuracy included in systematic reviews.

Authors:  Penny Whiting; Anne W S Rutjes; Johannes B Reitsma; Patrick M M Bossuyt; Jos Kleijnen
Journal:  BMC Med Res Methodol       Date:  2003-11-10       Impact factor: 4.615

View more
  49 in total

1.  Magnetic resonance imaging of pulmonary nodules: accuracy in a granulomatous disease-endemic region.

Authors:  Natália Henz Concatto; Guilherme Watte; Edson Marchiori; Klaus Irion; José Carlos Felicetti; José Jesus Camargo; Bruno Hochhegger
Journal:  Eur Radiol       Date:  2015-12-05       Impact factor: 5.315

2.  Comments on characterization of solitary pulmonary nodules with 18F-FDG PET/CT relative activity distribution analysis.

Authors:  Orazio Schillaci; Ferdinando F Calabria
Journal:  J Thorac Dis       Date:  2015-10       Impact factor: 2.895

3.  Integrating manual diagnosis into radiomics for reducing the false positive rate of 18F-FDG PET/CT diagnosis in patients with suspected lung cancer.

Authors:  Fei Kang; Wei Mu; Jie Gong; Shengjun Wang; Guoquan Li; Guiyu Li; Wei Qin; Jie Tian; Jing Wang
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-07-18       Impact factor: 9.236

Review 4.  The Pursuit of Noninvasive Diagnosis of Lung Cancer.

Authors:  Thomas Atwater; Christine M Cook; Pierre P Massion
Journal:  Semin Respir Crit Care Med       Date:  2016-10-12       Impact factor: 3.119

5.  Preclinical Evaluation of 4-[18F]Fluoroglutamine PET to Assess ASCT2 Expression in Lung Cancer.

Authors:  Mohamed Hassanein; Matthew R Hight; Jason R Buck; Mohammed N Tantawy; Michael L Nickels; Megan D Hoeksema; Bradford K Harris; Kelli Boyd; Pierre P Massion; H Charles Manning
Journal:  Mol Imaging Biol       Date:  2016-02       Impact factor: 3.488

6.  Glucose-corrected standardized uptake value (SUVgluc) is the most accurate SUV parameter for evaluation of pulmonary nodules.

Authors:  Amin Haghighat Jahromi; Farshad Moradi; Carl K Hoh
Journal:  Am J Nucl Med Mol Imaging       Date:  2019-10-15

Review 7.  Accuracy of mucocutaneous leishmaniasis diagnosis using polymerase chain reaction: systematic literature review and meta-analysis.

Authors:  Ciro Martins Gomes; Suleimy Cristina Mazin; Elisa Raphael dos Santos; Mariana Vicente Cesetti; Guilherme Albergaria Brízida Bächtold; João Henrique de Freitas Cordeiro; Fabrício Claudino Estrela Terra Theodoro; Fabiana dos Santos Damasco; Sebastián Andrés Vernal Carranza; Adriana de Oliveira Santos; Ana Maria Roselino; Raimunda Nonata Ribeiro Sampaio
Journal:  Mem Inst Oswaldo Cruz       Date:  2015-03-31       Impact factor: 2.743

8.  68Ga-NOTA-PRGD2 PET/CT for Integrin Imaging in Patients with Lung Cancer.

Authors:  Kun Zheng; Naixin Liang; Jingjing Zhang; Lixin Lang; Wei Zhang; Shanqing Li; Jun Zhao; Gang Niu; Fang Li; Zhaohui Zhu; Xiaoyuan Chen
Journal:  J Nucl Med       Date:  2015-10-01       Impact factor: 10.057

9.  Assessment of Fluorodeoxyglucose F18-Labeled Positron Emission Tomography for Diagnosis of High-Risk Lung Nodules.

Authors:  Amelia W Maiga; Stephen A Deppen; Sarah Fletcher Mercaldo; Jeffrey D Blume; Chandler Montgomery; Laszlo T Vaszar; Christina Williamson; James M Isbell; Otis B Rickman; Rhonda Pinkerman; Eric S Lambright; Jonathan C Nesbitt; Eric L Grogan
Journal:  JAMA Surg       Date:  2018-04-01       Impact factor: 14.766

Review 10.  Present and future roles of FDG-PET/CT imaging in the management of lung cancer.

Authors:  Kazuhiro Kitajima; Hiroshi Doi; Tomonori Kanda; Tomohiko Yamane; Tetsuya Tsujikawa; Hayato Kaida; Yukihisa Tamaki; Kozo Kuribayashi
Journal:  Jpn J Radiol       Date:  2016-04-27       Impact factor: 2.374

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.